

Accepted Manuscript

Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared to clinical trials: a multicenter retrospective study

Arvin Ighani, BMSc, Jorge R. Georgakopoulos, BSc, Neil H. Shear, MD, FRCPC, Scott Walsh, MD, FRCPC, Jensen Yeung, MD, FRCPC

PII: S0190-9622(17)32477-5

DOI: [10.1016/j.jaad.2017.09.067](https://doi.org/10.1016/j.jaad.2017.09.067)

Reference: YMJD 12045

To appear in: *Journal of American Dermatology*

Received Date: 17 August 2017

Revised Date: 22 September 2017

Accepted Date: 28 September 2017

Please cite this article as: Ighani A, Georgakopoulos JR, Shear NH, Walsh S, Yeung J, Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared to clinical trials: a multicenter retrospective study, *Journal of American Dermatology* (2017), doi: 10.1016/j.jaad.2017.09.067.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **Article Type:** Research Letter

2
3 **Title:** Short-term reasons for withdrawal and adverse events associated with apremilast therapy
4 for psoriasis in real-world practice compared to clinical trials: a multicenter retrospective study.

5
6 **Authors**

7 Arvin Ighani, BMSc,^a Jorge R Georgakopoulos, BSc,^b Neil H Shear, MD, FRCPC,^{c,d,e} Scott
8 Walsh, MD, FRCPC,^{c,d,e} and Jensen Yeung, MD, FRCPC^{c,d,e,f}

9
10 ^a Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

11 ^b Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada

12 ^c Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario,
13 Canada

14 ^d Sunnybrook Health Sciences Centre, Toronto, ON, Canada

15 ^e Women's College Hospital, Toronto, ON, Canada

16 ^f Proby Medical Research Inc, Waterloo, ON, Canada

17
18 **Corresponding Author**

19 Arvin Ighani, BMSc

20 Department of Dermatology

21 Faculty of Medicine, University of Toronto

22 1 King's College Circle, Toronto, ON, Canada, M5S 1A8

23 P: +1-647-204-4470, E: arvin.ighani@mail.utoronto.ca

24
25 **Funding Sources:** None.

26
27 **IRB Status:** This study was approved by the Research Ethics Board at Sunnybrook Health
28 Sciences Centre (190-2016) and Women's College Hospital (2016-0072-E).

29
30 **Conflicts of Interest:** Dr. Yeung has been a speaker and/or consultant and/or investigator for
31 AbbVie, Allergan, Amgen, Astellas, Boehringer Ingelheim, Celgene, Centocor, Coherus,
32 Dermira, Eli Lilly, Forward, Galderma, Janssen, Leo, Medimmune, Merck, Novartis, Pfizer,
33 Regeneron, and Takeda. Dr. Shear has been a consultant and/or speaker for AbbVie, Actelion,
34 Amgen, Celgene, Hospira, Janssen, Janssen Biotech, Lilly, Novartis, Sanofi, Genzyme, and
35 Takeda. Dr. Walsh has been a consultant for AbbVie, Amgen, Celgene, Janssen, and Lilly. Mr.
36 Georgakopoulos and Mr. Ighani have no conflicts of interest to declare.

37
38 **Word Count**

39 Abstract: N/A

40 Capsule summary: N/A

41 Text: 454

42 References: 4

43 Tables: 2

44 Figures: 0

45

46

Download English Version:

<https://daneshyari.com/en/article/8715160>

Download Persian Version:

<https://daneshyari.com/article/8715160>

[Daneshyari.com](https://daneshyari.com)